Scotto G, Grimaldi M
Department of Infectious Diseases, United Hospitals, Foggia, Italy.
Dig Dis Sci. 1998 Oct;43(10):2173-6. doi: 10.1023/a:1026693901012.
Twenty-four patients with chronic active HCV infection, nonresponders to a previous treatment cycle with recombinant interferon-alpha (r-IFNA), underwent retreatment with leukocyte (LE-) IFN-alpha. This was administered at the dose of 3 MU three times a week, for either six months (group A) or 12 months (group B). All patients were followed-up for a further 12 months. ALT levels significantly (P < 0.05) decreased in group A, with complete response in three cases and a partial response in a further three at the end of treatment. During follow-up all patients again showed increases in ALT values. In group B also ALT significantly (P < 0.05) decreased, with two complete and five partial responses. During follow-up, apart from two patients with partial responses who relapsed, all maintained their initial response. At the end of treatment HCV RNA was no longer detectable in complete responders of both groups, while it was found reduced in those partial responders who maintained their response during follow-up. Partially responding subjects treated for six months evidenced higher levels than those treated for 12 months. IFN-alpha retreatment could therefore be effective in previously nonresponding patients, with a change in the type of interferon administered and the use of higher dosages and/or longer treatment periods.
24例慢性活动性丙型肝炎病毒(HCV)感染患者,对先前重组干扰素α(r-IFNα)治疗周期无反应,接受白细胞(LE-)IFNα再治疗。以每周3次、每次3MU的剂量给药,持续6个月(A组)或12个月(B组)。所有患者进一步随访12个月。A组丙氨酸转氨酶(ALT)水平显著降低(P<0.05),治疗结束时3例完全缓解,另外3例部分缓解。随访期间,所有患者ALT值再次升高。B组ALT也显著降低(P<0.05),2例完全缓解,5例部分缓解。随访期间,除2例部分缓解患者复发外,所有患者均维持初始缓解状态。治疗结束时,两组完全缓解者HCV RNA均不再可检测到,而在随访期间维持缓解的部分缓解者中发现HCV RNA减少。接受6个月治疗的部分缓解者的HCV RNA水平高于接受12个月治疗者。因此,改变所用干扰素类型并使用更高剂量和/或更长治疗期,IFNα再治疗可能对先前无反应的患者有效。